Cytokine modulators as novel therapies for airway disease

Cytokines play a critical role in orchestrating and perpetuating inflammation in asthma and chronic obstructive pulmonary disease (COPD), and several specific cytokine and chemokine inhibitors are now in development for the future therapy of these diseases. Anti-interleukin (IL)‐5 is very effective at reducing peripheral blood and airway eosinophil numbers, but does not appear to be effective against symptomatic asthma. Inhibition of IL‐4 with soluble IL‐4 receptors has shown promising early results in asthma. Inhibitory cytokines, such as IL-10, interferons and IL-12 are less promising, as systemic delivery causes side-effects. Inhibition of tumour necrosis factor‐α may be useful in severe asthma and for treating severe COPD with systemic features. Many chemokines are involved in the inflammatory response of asthma and COPD and several low-molecular-weight inhibitors of chemokine receptors are in development. CCR3 antagonists (which block eosinophil chemotaxis) and CXCR2 antagonists (which block neutrophil and monocyte chemotaxis) are in clinical development for the treatment of asthma and COPD respectively. Because so many cytokines are involved in asthma, drugs that inhibit the synthesis of multiple cytokines may prove to be more useful; several such classes of drug are now in clinical development and any risk of side-effects with these nonspecific inhibitors may be reduced by the use of inhalational route of delivery.

[1]  J. Kips,et al.  Cytokines in asthma , 2001, European Respiratory Journal.

[2]  I. Adcock,et al.  Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophages. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  R. Egan,et al.  Th2 cytokines and asthma — The role of interleukin-5 in allergic eosinophilic disease , 2001, Respiratory research.

[4]  J. Steinke,et al.  Th2 cytokines and asthma — Interleukin-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists , 2001, Respiratory research.

[5]  R. Levitt,et al.  Th2 cytokines and asthma — Interleukin-9 as a therapeutic target for asthma , 2001, Respiratory research.

[6]  Stephen T Holgate,et al.  Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response , 2000, The Lancet.

[7]  K. Chung,et al.  Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic response , 2000, The Lancet.

[8]  P. Rutgeerts,et al.  Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease , 2000 .

[9]  H. Sarau,et al.  Identification of Potent, Selective Non-peptide CC Chemokine Receptor-3 Antagonist That Inhibits Eotaxin-, Eotaxin-2-, and Monocyte Chemotactic Protein-4-induced Eosinophil Migration* , 2000, The Journal of Biological Chemistry.

[10]  Y. Nasuhara,et al.  p38 MAP kinase and MKK‐1 co‐operate in the generation of GM‐CSF from LPS‐stimulated human monocytes by an NF‐κB‐independent mechanism , 2000, British journal of pharmacology.

[11]  C. Power,et al.  The strategy of blocking the chemokine system to combat disease , 2000, Immunological reviews.

[12]  J. Gutiérrez-Ramos,et al.  Non‐redundant functional groups of chemokines operate in a coordinate manner during the inflammatory response in the lung , 2000, Immunological reviews.

[13]  I. Adcock,et al.  Glucocorticoid Receptor Recruitment of Histone Deacetylase 2 Inhibits Interleukin-1β-Induced Histone H4 Acetylation on Lysines 8 and 12 , 2000, Molecular and Cellular Biology.

[14]  C. Dinarello Interleukin-18, a proinflammatory cytokine. , 2000, European cytokine network.

[15]  M. Peck,et al.  A Small Molecule Antagonist of Chemokine Receptors CCR1 and CCR3 , 2000, The Journal of Biological Chemistry.

[16]  S. Sanjar,et al.  Airway subepithelial fibrosis in a murine model of atopic asthma: suppression by dexamethasone or anti-interleukin-5 antibody. , 2000, American journal of respiratory cell and molecular biology.

[17]  E. Tagaya,et al.  Effect of suplatast tosilate, a Th2 cytokine inhibitor, on steroid-dependent asthma: a double-blind randomised study , 2000, The Lancet.

[18]  P. Barnes,et al.  New directions in allergic diseases: mechanism-based anti-inflammatory therapies. , 2000, The Journal of allergy and clinical immunology.

[19]  A. Markham,et al.  Infliximab: a review of its use in the management of rheumatoid arthritis. , 2000, Drugs.

[20]  P. Rothman,et al.  IL-4/IL-13 signaling beyond JAK/STAT. , 2000, The Journal of allergy and clinical immunology.

[21]  H. Simon,et al.  Treatment with IFN-a in corticosteroid-unresponsiveasthma , 2000 .

[22]  D E Griswold,et al.  Inhibition of p38 MAP kinase as a therapeutic strategy. , 2000, Immunopharmacology.

[23]  P. Hiemstra,et al.  Monocyte chemoattractant protein 1, interleukin 8, and chronic airways inflammation in COPD , 2000, The Journal of pathology.

[24]  R. Pauwels,et al.  A long-term study of the antiinflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma. , 2000, American journal of respiratory and critical care medicine.

[25]  P. Barnes,et al.  Endogenous inhibitory mechanisms in asthma. , 2000, American journal of respiratory and critical care medicine.

[26]  P. Barnes Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease. , 2000, American journal of respiratory and critical care medicine.

[27]  P. Barnes,et al.  Mechanisms in COPD: differences from asthma. , 2000, Chest.

[28]  C. Martínez-A,et al.  Cc Chemokine Receptor (Ccr)3/Eotaxin Is Followed by Ccr4/Monocyte-Derived Chemokine in Mediating Pulmonary T Helper Lymphocyte Type 2 Recruitment after Serial Antigen Challenge in Vivo , 2000, The Journal of experimental medicine.

[29]  J. Lafitte,et al.  IL-9 and its receptor in allergic and nonallergic lung disease: increased expression in asthma. , 2000, The Journal of allergy and clinical immunology.

[30]  A. Zlotnik,et al.  The biology of chemokines and their receptors. , 2000, Annual review of immunology.

[31]  S. Erzurum,et al.  Interleukin-9 Receptor Expression in Asthmatic Airways In Vivo , 2000, Lung.

[32]  M. Humbert,et al.  Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), and MCP-4), and C-C chemokine receptor 3 expression in bronchial biopsies from atopic and nonatopic (Intrinsic) asthmatics. , 1999, Journal of immunology.

[33]  L. Borish,et al.  Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. , 1999, American journal of respiratory and critical care medicine.

[34]  P. Barnes Therapeutic strategies for allergic diseases , 1999, Nature.

[35]  R. Maciewicz,et al.  New alpha-substituted succinate-based hydroxamic acids as TNFalpha convertase inhibitors. , 1999, Journal of medicinal chemistry.

[36]  S. Wenzel,et al.  Allergen-induced IL-9 directly stimulates mucin transcription in respiratory epithelial cells. , 1999, The Journal of clinical investigation.

[37]  J. Gutiérrez-Ramos,et al.  Eotaxin: from an eosinophilic chemokine to a major regulator of allergic reactions. , 1999, Immunology today.

[38]  K. Chung,et al.  Neutrophilic inflammation in severe persistent asthma. , 1999, American journal of respiratory and critical care medicine.

[39]  R. Stockley,et al.  The interrelationship of sputum inflammatory markers in patients with chronic bronchitis. , 1999, American journal of respiratory and critical care medicine.

[40]  R. Strieter,et al.  Monocyte chemoattractant protein-1 mediates cockroach allergen-induced bronchial hyperreactivity in normal but not CCR2-/- mice: the role of mast cells. , 1999, Journal of immunology.

[41]  M. Adachi,et al.  Effect of suplatast tosilate (IPD-1151T) on cytokine production by allergen-specific human Th1 and Th2 cell lines. , 1999, Life sciences.

[42]  Y. Nasuhara,et al.  Differential IkappaB kinase activation and IkappaBalpha degradation by interleukin-1beta and tumor necrosis factor-alpha in human U937 monocytic cells. Evidence for additional regulatory steps in kappaB-dependent transcription. , 1999, The Journal of biological chemistry.

[43]  D. Faulds,et al.  Etanercept: a review of its use in rheumatoid arthritis. , 1999, Drugs.

[44]  K. Holroyd,et al.  IL-9 pathway in asthma: new therapeutic targets for allergic inflammatory disorders. , 1999, The Journal of allergy and clinical immunology.

[45]  S. Christensen,et al.  Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic. , 1999, Pulmonary pharmacology & therapeutics.

[46]  D. Hilton,et al.  Cutting edge: SOCS-1 is a potent inhibitor of IL-4 signal transduction. , 1999, Journal of immunology.

[47]  P. Barnes Strategies for novel COPD therapies. , 1999, Pulmonary pharmacology & therapeutics.

[48]  G. Hunninghake,et al.  Both Erk and p38 kinases are necessary for cytokine gene transcription. , 1999, American journal of respiratory cell and molecular biology.

[49]  T. Mosmann,et al.  Effects of Th2 cytokines on chemokine expression in the lung: IL-13 potently induces eotaxin expression by airway epithelial cells. , 1999, Journal of immunology.

[50]  D. Umetsu,et al.  The kinetics of change in cytokine production by CD4 T cells during conventional allergen immunotherapy. , 1999, The Journal of allergy and clinical immunology.

[51]  P. Foster,et al.  STAT6: an intracellular target for the inhibition of allergic disease. , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[52]  D D Donaldson,et al.  Interleukin-13: central mediator of allergic asthma , 1998 .

[53]  K. Chung,et al.  Inflammatory mediators of asthma: an update. , 1998, Pharmacological reviews.

[54]  M. Kool,et al.  Prevention of Th2-like cell responses by coadministration of IL-12 and IL-18 is associated with inhibition of antigen-induced airway hyperresponsiveness, eosinophilia, and serum IgE levels. , 1998, Journal of immunology.

[55]  P. Barnes,et al.  Inhibitory cytokines in asthma. , 1998, Molecular medicine today.

[56]  L. Rosenwasser,et al.  Biologic activities of IL-1 and its role in human disease. , 1998, The Journal of allergy and clinical immunology.

[57]  J. Greve,et al.  An immune cell-selective interleukin 4 agonist. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[58]  P. Foster,et al.  A novel T cell-regulated mechanism modulating allergen-induced airways hyperreactivity in BALB/c mice independently of IL-4 and IL-5. , 1998, Journal of immunology.

[59]  C. Akdis,et al.  Role of interleukin 10 in specific immunotherapy. , 1998, The Journal of clinical investigation.

[60]  R. Hertzberg,et al.  Identification of a Potent, Selective Non-peptide CXCR2 Antagonist That Inhibits Interleukin-8-induced Neutrophil Migration* , 1998, The Journal of Biological Chemistry.

[61]  M. M. Teixeira,et al.  Effect of PDE4 inhibitors on zymosan‐induced IL‐8 release from human neutrophils: synergism with prostanoids and salbutamol , 1998, British journal of pharmacology.

[62]  A. Luster,et al.  Chemokines--chemotactic cytokines that mediate inflammation. , 1998, The New England journal of medicine.

[63]  T. Torphy Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. , 1998, American journal of respiratory and critical care medicine.

[64]  J. Banchereau,et al.  Interleukin-4 and interleukin-13: their similarities and discrepancies. , 1998, International reviews of immunology.

[65]  C. Gabay,et al.  Interleukin-1 receptor antagonist: role in biology. , 1998, Annual review of immunology.

[66]  L Adorini,et al.  The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. , 1998, Annual review of immunology.

[67]  K. Chung,et al.  Inhaled corticosteroids increase interleukin-10 but reduce macrophage inflammatory protein-1alpha, granulocyte-macrophage colony-stimulating factor, and interferon-gamma release from alveolar macrophages in asthma. , 1998, American journal of respiratory and critical care medicine.

[68]  C. Mackay,et al.  Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma. Association with airway hyperresponsiveness and predominant co‐localization of eotaxin mRNA to bronchial epithelial and endothelial cells , 1997, European journal of immunology.

[69]  A. Proudfoot,et al.  The CC chemokine antagonist Met‐RANTES inhibits eosinophil effector functions through the chemokine receptors CCR1 and CCR3 , 1997, European journal of immunology.

[70]  S. Holgate,et al.  Release of RANTES, MIP-1 alpha, and MCP-1 into asthmatic airways following endobronchial allergen challenge. , 1997, American journal of respiratory and critical care medicine.

[71]  J. Leonard,et al.  Effects of Single-Dose Interleukin-12 Exposure on Interleukin-12–Associated Toxicity and Interferon-γ Production , 1997 .

[72]  S. Wenzel,et al.  Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. , 1997, American journal of respiratory and critical care medicine.

[73]  R. Martin,et al.  Eosinophil-associated TGF-beta1 mRNA expression and airways fibrosis in bronchial asthma. , 1997, American journal of respiratory cell and molecular biology.

[74]  T. Yoneda,et al.  Airway inflammation in COPD assessed by sputum levels of interleukin-8. , 1997, Chest.

[75]  L. Aarden,et al.  Reduced production of IL-12 and IL-12-dependent IFN-gamma release in patients with allergic asthma. , 1997, Journal of immunology.

[76]  M. Goldman,et al.  IL-10: a potential therapy for allergic inflammation? , 1997, Immunology today.

[77]  J. Zurlinden New treatments for asthma. , 1997, Nursing spectrum.

[78]  S. Levy,et al.  An ovalbumin-IL-12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen-specific IgE production. , 1997, Journal of immunology.

[79]  M. Karin,et al.  Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. , 1997, The New England journal of medicine.

[80]  F. Finkelman,et al.  Interleukin-4 receptor blockade prevents airway responses induced by antigen challenge in mice. , 1997, The American journal of physiology.

[81]  P. Hogan,et al.  Transcription factors of the NFAT family: regulation and function. , 1997, Annual review of immunology.

[82]  J. Leonard,et al.  Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. , 1997, Blood.

[83]  K. Chung,et al.  Expression of RANTES mRNA and protein in airways of patients with mild asthma. , 1996, American journal of respiratory and critical care medicine.

[84]  M. Cybulsky,et al.  Eosinophil recruitment to the lung in a murine model of allergic inflammation. The role of T cells, chemokines, and adhesion receptors. , 1996, The Journal of clinical investigation.

[85]  A. Sousa,et al.  Expression of interleukin-1 beta (IL-1beta) and interleukin-1 receptor antagonist (IL-1ra) on asthmatic bronchial epithelium. , 1996, American journal of respiratory and critical care medicine.

[86]  E. Gelfand,et al.  Nebulized IFN-gamma inhibits the development of secondary allergic responses in mice. , 1996, Journal of immunology.

[87]  L. Fabbri,et al.  Airway eosinophilia and expression of interleukin‐5 protein in asthma and in exacerbations of chronic bronchitis , 1996, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[88]  S. Wenzel,et al.  Interleukin-10 regulation in normal subjects and patients with asthma. , 1996, Journal of Allergy and Clinical Immunology.

[89]  S. Durham,et al.  Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. , 1996, The Journal of allergy and clinical immunology.

[90]  N. Barnes,et al.  Double-blind, placebo-controlled study of cyclosporin A as a corticosteroid-sparing agent in corticosteroid-dependent asthma. , 1996, American journal of respiratory and critical care medicine.

[91]  R. Rogers,et al.  Elevated TNF-alpha production by peripheral blood monocytes of weight-losing COPD patients. , 1996, American journal of respiratory and critical care medicine.

[92]  P. Barnes,et al.  Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. , 1996, American journal of respiratory and critical care medicine.

[93]  J. Bousquet,et al.  Different cytokine patterns in bronchial biopsies in asthma and chronic bronchitis. , 1996, Respiratory medicine.

[94]  R. Egan,et al.  Biology of interleukin‐5 and its relevance to allergic disease , 1996, Allergy.

[95]  J. Dayer,et al.  IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. , 1995, The Journal of clinical investigation.

[96]  F. Finkelman,et al.  Interleukin 12 inhibits antigen-induced airway hyperresponsiveness, inflammation, and Th2 cytokine expression in mice , 1995, The Journal of experimental medicine.

[97]  R. Egan,et al.  Effects of an antibody to interleukin-5 in a monkey model of asthma. , 1995, American journal of respiratory and critical care medicine.

[98]  D. Leduc,et al.  Interleukin-10 inhibits antigen-induced cellular recruitment into the airways of sensitized mice. , 1995, The Journal of clinical investigation.

[99]  Richard J Martin,et al.  The effects of nebulized recombinant interferon-γ in asthmatic airways , 1995 .

[100]  R. Egan,et al.  Inhibitory effect of the TRFK-5 anti-IL-5 antibody in a guinea pig model of asthma. , 1993, The American review of respiratory disease.

[101]  R. Pauwels,et al.  The potential role of tumour necrosis factor a in asthma , 1993, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.